Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in:

10.01.2021 | Clinical trial

Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer

verfasst von: G. F. P. Aleixo, H. Yu, Y. T. Chen, K. A. Nyrop, R. J. Louie, A. M. Deal, S. S. Shachar, H. B. Muss, G. R. Williams

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Myosteatosis (intramuscular adiposity) is predictive of chemotherapy toxicity in women undergoing adjuvant chemotherapy for breast cancer (BC). We evaluated a novel, user-friendly and cost-effective technique utilizing a Picture Archiving and Communication Systems (PACS) tool that is readily available in the electronic medical record (EMR), using skeletal muscle density (SMD) to detect myosteatosis and then compared PACS results with those derived from widely used body composition software (SliceOMatic, QC, Canada).

Methods

Using retrospective data from a sample of women with early BC (Stage I-III) who had CT scan and received chemotherapy. Pearson correlation coefficients were used to compare SliceOMatic with PACS results. Associations of PACS results with chemotherapy-related adverse events were evaluated using multivariable (MV) log-binomial models adjusted for age, race, BMI, anthracycline-based therapy, and number of comorbidities.

Results

In 338 patients, mean age was 51, 32% were non-white, and 40% had obesity (BMI ≥ 30 kg/m2). Correlation of SMD using SliceOMatic whole muscle measurements with PACS psoas muscle was 0.76 (p < .0001) and with PACS erector spinae muscle 0.91 (p < .0001). Using PACS psoas muscle, myosteatosis was associated with any adverse event [RR 1.66, CI 1.22–2.26 (p < .0001)], dose reduction [RR 1.63, CI 1.01–2.65 (p = .05)], and early treatment discontinuation [RR 2.14, CI 1.10–4.14 (p = 0.03)]. Using PACS erector spinae muscle, myosteatosis was associated any adverse event [RR 1.59, CI 1.11–2.27 (p = 0.01)] and dose reduction [RR 1.91, CI 1.07–3.42 (p = .03)].

Conclusion and relevance

Skeletal muscle density measures using PACS correlated strongly with SliceOMatic results and both are similarly predictive of chemotherapy-related adverse events
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Sueda T, Takahasi H, Nishimura J et al (2018) Impact of low muscularity and myosteatosis on long-term outcome after curative colorectal cancer surgery: a propensity score-matched analysis. Dis Colon Rectum 61(3):364–374CrossRef
2.
Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4(6):798–804CrossRef
3.
4.
5.
6.
Caffrey C, Cairns C, Rome V (2020) Trends in electronic health record use among residential care communities: United States, 2012, 2014, and 2016. Natl Health Stat Rep 140:1–10
7.
Kalafateli M, Karatzas A, Tsiaoussis G et al (2018) Muscle fat infiltration assessed by total psoas density on computed tomography predicts mortality in cirrhosis. Ann Gastroenterol 31(4):491–498PubMedPubMedCentral
8.
Herrod PJJ, Boyd-Carson H, Doleman B et al (2019) Quick and simple; psoas density measurement is an independent predictor of anastomotic leak and other complications after colorectal resection. Tech Coloproctol 23(2):129–134CrossRef
9.
10.
Amini B, Boyle SP, Boutin RD, Lenchik L (2019) Approaches to assessment of muscle mass and myosteatosis on computed tomography: a systematic review. J Gerontol A 74(10):1671–1678CrossRef
11.
Kroenke CH, Prado CM, Meyerhardt JA et al (2018) Muscle radiodensity and mortality in patients with colorectal cancer. Cancer 124(14):3008–3015CrossRef
12.
Overholser BR, Sowinski KM (2008) Biostatistics primer: part 2. Nutr Clin Pract 23(1):76–84CrossRef
13.
Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E (2015) Breast cancer risk factors. Prz Menop 14(3):196–202
14.
Klepin HD, Pitcher BN, Ballman KV et al (2014) Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract 10(5):e285-292CrossRef
15.
Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR (2020) Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol 145:102839CrossRef
16.
Van Rijssen LB, van Huijgevoort NC, Coelen RJ et al (2017) Skeletal muscle quality is associated with worse survival after pancreatoduodenectomy for periampullary, nonpancreatic cancer. Ann Surg Oncol 24(1):272–280CrossRef
17.
van Vugt J, Alferink LJ, Büttner S, Metselaar H, IJzermans J (2018) Reply to: “May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?” and “has the time come for using MELD-Sarcopenia score?” J Hepatol 68(6):1326CrossRef
18.
Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539–1547CrossRef
19.
Cespedes Feliciano EM, Chen WY, Bradshaw PT et al (2019) Adipose tissue distribution and cardiovascular disease risk among breast cancer survivors. J Clin Oncol 37:2528CrossRef
20.
Abdel-Rahman O (2019) Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. Clin Transl Oncol 21(2):239–245CrossRef
21.
Yamashita M, Kamiya K, Matsunaga A et al (2017) Prognostic value of psoas muscle area and density in patients who undergo cardiovascular surgery. Can J Cardiol 33(12):1652–1659CrossRef
22.
Lo WD, Evans DC, Yoo T (2018) Computed tomography-measured psoas density predicts outcomes after enterocutaneous fistula repair. JPEN J Parenter Enter Nutr 42(1):176–185
23.
Valenzuela PL, Maffiuletti NA, Tringali G, De Col A, Sartorio A (2020) Obesity-associated poor muscle quality: prevalence and association with age, sex, and body mass index. BMC Musculoskelet Disord 21(1):200CrossRef
Metadaten
Titel
Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer
verfasst von
G. F. P. Aleixo
H. Yu
Y. T. Chen
K. A. Nyrop
R. J. Louie
A. M. Deal
S. S. Shachar
H. B. Muss
G. R. Williams
Publikationsdatum
10.01.2021
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06061-y

Weitere Artikel der Ausgabe 2/2021

Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset

  • Epidemiology

Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients

  • Preclinical study

Body composition and breast cancer risk and treatment: mechanisms and impact

  • Review

Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes

  • Epidemiology

New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)

  • Clinical trial

Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer

  • Epidemiology

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise